Presenting characteristics of @entity1 with duodenal @entity1066 and outcome of medical treatment in controlled clinical trials using XXXX and diethylamine persilate to treat @entity1066 attack and diethylamine persilate and placebo to prevent relapses.

@entity1 @entity6136 @entity4444 @entity548 @entity1066 @entity4773 @entity3009 @entity73140
A double-blind controlled clinical trial on the medical treatment of the acute episode of duodenal @entity1066 and the prevention of symptomatic relapses was performed. A total of 164 @entity1 with active duodenal @entity1066 were either treated with @entity4444 1 g/day (70 @entity1 ), @entity73140 ( @entity6136 ) 1.5 g/day (64 @entity1 ) or @entity6136 2.5 g/day (30 @entity1 ). @entity6136 is an allegedly protective agent stimulating mucosal @entity3009 synthesis. Cumulative healing rates after 4 weeks in the 3 groups were 66, 28 and 28% and after 8 weeks 94, 70 and 63%, respectively. One hundred and five @entity1 with healed duodenal @entity1066 received, in a second double-blind study, either @entity6136 0.5 g/day or placebo. Thus, @entity1066 was more rapid with @entity4444 than with @entity6136 . @entity6136 did not prevent relapses. No presenting characteristic was associated with slow healing. Three presenting characteristics--smoking, teetotalling and @entity548 episode in the past--were associated with early symptomatic relapse. The present study was compared with a previous study performed by the same group of investigators using a similar study protocol. In both trials, an early relapse was associated with smoking. No other presenting characteristic was identified which in both trials was associated with slow healing or early symptomatic relapse. Thus, smoking appears to be the only one of the commonly available presenting characteristics which allows a prediction of the course of @entity4773 .
